JP2006523185A5 - - Google Patents

Download PDF

Info

Publication number
JP2006523185A5
JP2006523185A5 JP2006503571A JP2006503571A JP2006523185A5 JP 2006523185 A5 JP2006523185 A5 JP 2006523185A5 JP 2006503571 A JP2006503571 A JP 2006503571A JP 2006503571 A JP2006503571 A JP 2006503571A JP 2006523185 A5 JP2006523185 A5 JP 2006523185A5
Authority
JP
Japan
Prior art keywords
hybrid antigen
tumor
medicament
heat shock
shock protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006503571A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006523185A (ja
Filing date
Publication date
Priority claimed from US10/776,521 external-priority patent/US7420037B2/en
Application filed filed Critical
Publication of JP2006523185A publication Critical patent/JP2006523185A/ja
Publication of JP2006523185A5 publication Critical patent/JP2006523185A5/ja
Pending legal-status Critical Current

Links

JP2006503571A 2003-02-13 2004-02-13 改良された熱ショックタンパク質に基づくワクチンおよび免疫療法 Pending JP2006523185A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US44714203P 2003-02-13 2003-02-13
US46246903P 2003-04-11 2003-04-11
US46374603P 2003-04-18 2003-04-18
US50341703P 2003-09-16 2003-09-16
US10/776,521 US7420037B2 (en) 2003-02-13 2004-02-12 Heat shock protein-based vaccines and immunotherapies
PCT/US2004/004340 WO2004071457A2 (en) 2003-02-13 2004-02-13 Improved heat shock protein-based vaccines and immunotherapies

Publications (2)

Publication Number Publication Date
JP2006523185A JP2006523185A (ja) 2006-10-12
JP2006523185A5 true JP2006523185A5 (enExample) 2007-05-10

Family

ID=32873068

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006503571A Pending JP2006523185A (ja) 2003-02-13 2004-02-13 改良された熱ショックタンパク質に基づくワクチンおよび免疫療法

Country Status (6)

Country Link
US (1) US7420037B2 (enExample)
EP (1) EP1622563A4 (enExample)
JP (1) JP2006523185A (enExample)
AU (1) AU2004212003B2 (enExample)
CA (1) CA2520591A1 (enExample)
WO (1) WO2004071457A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6761892B1 (en) * 1995-08-18 2004-07-13 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
US7309491B2 (en) * 2003-04-11 2007-12-18 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
WO2004091493A2 (en) * 2003-04-11 2004-10-28 Antigenics, Inc. Improved heat shock protein-based vaccines and immunotherapies
US7485312B2 (en) * 2003-06-20 2009-02-03 Dade Behring Marburg Gmbh Surface protein (HBsAg) variant of the hepatitis B virus
AU2004274430A1 (en) * 2003-09-12 2005-03-31 Antigenics, Inc. Vaccine for treatment and prevention of herpes simplex virus infection
WO2005067980A2 (en) * 2004-01-12 2005-07-28 Pointilliste, Inc. Design of therapeutics and therapeutics
AU2006236294A1 (en) 2005-04-19 2006-10-26 Eli Lilly And Company Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease
EP2632939A4 (en) * 2010-10-25 2014-05-14 Academia Sinica Taiwan CANCER-TREATED PEPTIDES AND THEIR USE IN CANCER TREATMENT AND DIAGNOSIS
EP2734231A1 (en) * 2011-07-21 2014-05-28 Biotech Tools S.A. Dosage of dnak
EP3294324A1 (en) * 2015-05-13 2018-03-21 Agenus Inc. Vaccines for treatment and prevention of cancer
WO2018187515A1 (en) 2017-04-04 2018-10-11 Avidea Technologies, Inc. Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
US11065317B2 (en) 2018-04-26 2021-07-20 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
AU2020315917A1 (en) * 2019-07-24 2022-02-17 Agenus Inc. Antigenic polypeptides and methods of use thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8727030D0 (en) 1987-11-18 1987-12-23 Imp Cancer Res Tech Production of monoclonal antibodies
US5498538A (en) 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US5348945A (en) 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
IL99821A (en) 1991-10-22 1996-07-23 Yeda Res & Dev Antitumor vaccines comprising cells transfected with a gene encoding human il-6
GB9202219D0 (en) * 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
GB9223816D0 (en) 1992-11-13 1993-01-06 Medical Res Council Heat shock proteins and the treatment of tumours
PT700445E (pt) 1993-06-04 2002-07-31 Whitehead Biomedical Inst Proteinas de stress e suas utilizacoes
US5750119A (en) 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5541109A (en) 1994-04-19 1996-07-30 Rhone-Poulenc Rorer Pharmaceuticals Inc. Expression cloning of c-src SH3-domain binding proteins
WO1997006821A1 (en) * 1995-08-18 1997-02-27 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
AU727673B2 (en) 1995-09-13 2000-12-21 Fordham University Therapeutic and prophylactic methods using heat shock proteins
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5985270A (en) 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US6127393A (en) 1995-12-29 2000-10-03 Novactyl, Inc. Antiproliferative, antiinfective, antiinflammatory, autologous immunization agent and method
WO1997026910A2 (de) 1996-01-27 1997-07-31 Max-Delbrück-Centrum für Molekulare Medizin Tumorimpfstoff für die immuntherapie von malignen tumoren
AU736318B2 (en) 1996-11-26 2001-07-26 Nventa Biopharmaceuticals Corporation Immune responses using compositions containing stress proteins
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
WO1998035705A1 (en) 1997-02-18 1998-08-20 Whitehead Institute For Biomedical Research Use of heat shock proteins to deliver moieties into cells
US5962262A (en) 1997-07-25 1999-10-05 Incyte Pharmaceuticals, Inc. Human heat shock 27 like protein
EP1027070A4 (en) * 1997-10-31 2004-08-18 Sloan Kettering Institutefor C CONJUGATES FROM HEAT SHOCK PROTEIN-BINDING PEPTIDES
ES2439014T3 (es) 1998-02-20 2014-01-21 The University Of Miami Complejo de péptido antigénico-proteína de choque térmico modificada
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
HUP0302681A3 (en) 2000-04-17 2006-11-28 Hoe Mee Irvington Javelinization of protein antigens to heat shock proteins
US20040043419A1 (en) 2001-04-17 2004-03-04 Rothman James E. Javelinization of protein antigens to heat shock proteins
US20040071656A1 (en) 2001-12-26 2004-04-15 Felix Wieland Modulation of heat-shock-protein-based immunotherapies
US7309491B2 (en) 2003-04-11 2007-12-18 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies

Similar Documents

Publication Publication Date Title
JP2006523185A5 (enExample)
ES2676630T3 (es) Control inmunogénico de tumores y células tumorales
JP2012511322A5 (enExample)
JP2010516290A5 (enExample)
JP2008535800A5 (enExample)
JP2015509707A5 (enExample)
CN104918637A (zh) 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
FI2970398T3 (fi) Rsv f -prefuusioproteiineja ja niiden käyttö
JP2011521662A5 (enExample)
TWI455721B (zh) 癌疫苗組合物
JP2018509935A5 (enExample)
JP2008530245A5 (enExample)
JP2012500006A5 (enExample)
HRP20190799T1 (hr) Imunocitokini na bazi il-15 i sushi domene il-15r alfa
JP2010500399A5 (enExample)
JP2012526839A5 (enExample)
WO2003090686A3 (en) Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
JP2009515831A5 (enExample)
AU2015204503A1 (en) Novel vaccines against HPV and HPV-related diseases
JP2016502515A5 (enExample)
CN111565746A (zh) 用于预防和治疗多种黄病毒的mhc i类相关肽
JP2009520758A5 (enExample)
JP2019531293A5 (enExample)
JP2015533376A5 (enExample)
JP2012504602A5 (enExample)